25.74
Acadia Pharmaceuticals Inc stock is traded at $25.74, with a volume of 3.38M.
It is up +3.85% in the last 24 hours and up +14.05% over the past month.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
See More
Previous Close:
$24.79
Open:
$24.97
24h Volume:
3.38M
Relative Volume:
1.64
Market Cap:
$4.34B
Revenue:
$890.53M
Net Income/Loss:
$30.57M
P/E Ratio:
143.00
EPS:
0.18
Net Cash Flow:
$80.53M
1W Performance:
+1.62%
1M Performance:
+14.05%
6M Performance:
+29.02%
1Y Performance:
+64.16%
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ACAD
Acadia Pharmaceuticals Inc
|
25.74 | 4.23B | 890.53M | 30.57M | 80.53M | 0.18 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-21-25 | Upgrade | Deutsche Bank | Hold → Buy |
Feb-11-25 | Initiated | Deutsche Bank | Hold |
Jan-03-25 | Downgrade | Guggenheim | Buy → Neutral |
Oct-10-24 | Resumed | Raymond James | Mkt Perform |
Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
Mar-12-24 | Reiterated | Needham | Buy |
Jan-30-24 | Initiated | Robert W. Baird | Outperform |
Jan-24-24 | Upgrade | Needham | Hold → Buy |
Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
Dec-13-23 | Initiated | Citigroup | Buy |
Dec-12-23 | Initiated | Deutsche Bank | Buy |
Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
Oct-17-23 | Initiated | UBS | Buy |
Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
Nov-01-22 | Initiated | Loop Capital | Hold |
Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Sep-23-21 | Resumed | Needham | Hold |
Jun-10-21 | Initiated | Berenberg | Hold |
Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
Mar-09-21 | Downgrade | Stifel | Buy → Hold |
Dec-16-20 | Initiated | Mizuho | Buy |
Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
Aug-25-20 | Initiated | Raymond James | Outperform |
Aug-20-20 | Initiated | Morgan Stanley | Overweight |
Jul-07-20 | Upgrade | Stifel | Hold → Buy |
Apr-16-20 | Initiated | Jefferies | Buy |
Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
Mar-06-20 | Initiated | Citigroup | Buy |
Dec-16-19 | Initiated | Guggenheim | Buy |
Oct-24-19 | Initiated | Oppenheimer | Perform |
Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
Jul-23-19 | Reiterated | Needham | Buy |
Dec-10-18 | Initiated | Canaccord Genuity | Hold |
Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
Aug-09-18 | Reiterated | Stifel | Hold |
Aug-07-18 | Initiated | Stifel | Hold |
Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
Acadia Pharma EVP Schneyer sells $554k in stock By Investing.com - Investing.com South Africa
Acadia Pharma EVP Schneyer sells $554k in stock - Investing.com
What makes ACADIA Pharmaceuticals Inc. stock price move sharplyPortfolio Update Report & Real-Time Market Sentiment Reports - beatles.ru
Will ACADIA Pharmaceuticals Inc. Recover After Recent Decline2025 Top Gainers & Verified Momentum Watchlists - newsyoung.net
High Growth Tech Stocks To Watch In The US August 2025 - simplywall.st
ACADIA Pharmaceuticals’ SWOT analysis: stock poised for growth amid challenges - Investing.com
Statutory Earnings May Not Be The Best Way To Understand ACADIA Pharmaceuticals' (NASDAQ:ACAD) True Position - 富途牛牛
Shareholders In ACADIA Pharmaceuticals (NASDAQ:ACAD) Should Look Beyond Earnings For The Full Story - Yahoo Finance
Mizuho lowers Acadia Pharmaceuticals stock price target to $22 from $32 - Investing.com Nigeria
Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates - MSN
Acadia Pharmaceuticals at Canaccord Conference: Strategic Growth and Innovation By Investing.com - Investing.com Nigeria
Acadia Pharmaceuticals at Canaccord Conference: Strategic Growth and Innovation - Investing.com
Acadia Pharmaceuticals stock hits 52-week high at 25.24 USD By Investing.com - Investing.com India
Acadia Pharmaceuticals stock hits 52-week high at 25.24 USD - Investing.com
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 11, 2025 - BioSpace
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
JMP Securities Boosts ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $38.00 - MarketBeat
The Goldman Sachs Group Issues Positive Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price - MarketBeat
Buy Rating on ACADIA Pharmaceuticals Driven by Daybue’s Sales Growth and Market Expansion - TipRanks
UBS Raises Price Target for ACADIA Pharmaceuticals to $36 - AInvest
Results: ACADIA Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Yahoo Finance
Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth - MSN
Acadia Pharmaceuticals shares rise 1.05% intraday after UBS raised price target to $36. - AInvest
RBC Capital Remains a Buy on ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $17 to $40 - 富途牛牛
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Q2 2025 Earnings Call Transcript - Insider Monkey
Earnings Beat: ACADIA Pharmaceuticals Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - 富途牛牛
ACADIA Pharmaceuticals Second Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Shares Surge 3.07% to New Peak on Q2 Earnings, Patent Wins - AInvest
ACADIA Pharmaceuticals: Strong Growth and Undervalued Pipeline Support Buy Rating - TipRanks
Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday - MSN
Acadia Pharmaceuticals Reports Strong Q2 2025 Growth - The Globe and Mail
ACADIA Pharmaceuticals Reports Strong Q2 2025 Earnings - TipRanks
Acadia Pharmaceuticals stock price target raised to $24 from $18 at Stifel - Investing.com Canada
Mizuho Maintains Neutral Rating, Raises Price Target for ACADIA Pharmaceuticals to $24 - AInvest
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $17 to $38 - 富途牛牛
Mizuho raises Acadia Pharmaceuticals stock price target on solid earnings By Investing.com - Investing.com Canada
Mizuho raises Acadia Pharmaceuticals stock price target on solid earnings - Investing.com
Acadia Pharmaceuticals price target raised to $38 from $37 at Citizens JMP - TipRanks
Acadia Pharmaceuticals price target raised to $27 from $23 at BofA - TipRanks
Acadia Pharmaceuticals Beats Q2 Earnings ForecastsNews and Statistics - IndexBox
Acadia: Q2 Earnings Snapshot - New Haven Register
Acadia Pharmaceuticals stock price target raised to $38 from $37 at Citizens JMP - Investing.com Australia
Acadia Pharmaceuticals shares rise 2.10% premarket after FDA approves expanded indication for AJOVY. - AInvest
Acadia Pharmaceuticals Raises Guidance As Sales Climb In Q2 - Finimize
Earnings call transcript: ACADIA Pharmaceuticals Q2 2025 beats forecasts By Investing.com - Investing.com Canada
Instagram Rolls Out New Features for Personalized Content Discovery and Sharing - AInvest
ACADIA Pharmaceuticals Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:ACAD) - Seeking Alpha
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):